Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 6,115 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker sold 6,115 shares of Pacira BioSciences stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total value of $143,702.50. Following the sale, the senior vice president owned 62,284 shares in the company, valued at $1,463,674. The trade was a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pacira BioSciences Trading Down 1.6%

NASDAQ PCRX opened at $22.99 on Friday. The stock has a market capitalization of $904.66 million, a price-to-earnings ratio of 191.60 and a beta of 0.29. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $27.64. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35. The business’s fifty day moving average is $23.58 and its 200-day moving average is $23.27.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The business had revenue of $177.38 million for the quarter, compared to the consensus estimate of $171.80 million. Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.65 earnings per share. Equities research analysts predict that Pacira BioSciences, Inc. will post 1.91 EPS for the current year.

Hedge Funds Weigh In On Pacira BioSciences

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its holdings in shares of Pacira BioSciences by 2.0% in the first quarter. Bank of America Corp DE now owns 188,437 shares of the company’s stock worth $4,259,000 after acquiring an additional 3,630 shares during the period. Amundi bought a new position in shares of Pacira BioSciences in the first quarter worth $309,000. California State Teachers Retirement System boosted its holdings in shares of Pacira BioSciences by 44.2% in the first quarter. California State Teachers Retirement System now owns 61,306 shares of the company’s stock worth $1,386,000 after acquiring an additional 18,806 shares during the period. Empowered Funds LLC boosted its holdings in shares of Pacira BioSciences by 21.6% in the first quarter. Empowered Funds LLC now owns 276,776 shares of the company’s stock worth $6,255,000 after acquiring an additional 49,171 shares during the period. Finally, Quantinno Capital Management LP boosted its holdings in shares of Pacira BioSciences by 45.6% in the first quarter. Quantinno Capital Management LP now owns 20,453 shares of the company’s stock worth $462,000 after acquiring an additional 6,410 shares during the period. 99.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PCRX shares. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Needham & Company LLC increased their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, May 1st. Royal Bank Of Canada increased their price objective on Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a report on Friday, May 1st. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Finally, Barclays reduced their price objective on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pacira BioSciences has an average rating of “Hold” and an average target price of $29.40.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.